DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07022977

CompletedPhase 1

A Study of MET233 in Individuals With Obesity or Overweight

A Randomized, Double-blind, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MET233 in Otherwise Healthy Adult Participants With Obesity or Overweight

Lead sponsor

Pfizer

Asset

MET233

Subcutaneous · Amylin analog

Listed sites

1

Recruiting sites

—

Enrollment

144

actual

Study population

Obesity / overweight

Key I/E criteria

•BMI 27-38•Healthy volunteers

Primary endpoint

•Occurrence of Treatment Emergent Adverse Events

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07022977
Org study IDMET233-24-101
Secondary IDC6501001Alias Study Number

Timeline

Milestones

Study start2024-11-06actual
Study first posted2025-06-15actual
Primary completion2026-04-21actual
Study completion2026-04-21actual
Last update posted2026-05-26actual

Assets

Investigational agents

MET233

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
Maximum age70 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

•Adult (≥18 to ≤70 years) male and female participants with obesity or overweight (BMI 27.0 kg/m2 to 38.0 kg/m2, inclusive) but otherwise healthy.

Exclusion criteria

•Female who is lactating or who is pregnant according to the pregnancy test at the Screening visit or prior to the first study drug administration
•Seated blood pressure higher than 160/95 mmHg at the Screening visit
•Elevated resting pulse greater than 100 beats per minute at Screening visit
•Presence of clinically significant ECG abnormalities
•Diagnosis of diabetes (type 1 or type 2)
•Participation in a weight loss program with or without pharmacotherapy during the 3 months prior to study administration
•Obesity induced by endocrinologic disorders (e.g., Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., Melanocortin 4 Receptor deficiency or Prader-Willi Syndrome).

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK
6
Weight & body composition
1

Weight & body composition

1 endpoint
Secondary/protocol endpoint

Percent change from baseline in body weight at the protocol-specified weekly post-baseline measurements

Time frame:Part A (Baseline to Day 85), Part B (Baseline to Day 113), Part C (Baseline to Day 162), Part D (Baseline to Day 239)

percent change from baseline, improvement

Safety / tolerability / PK

6 endpoints
Primary/protocol endpoint

Occurrence of Treatment Emergent Adverse Events

Time frame:Part A (Baseline to Day 85), Part B (Baseline to Day 113), Part C (Baseline to Day 162), Part D (Baseline to Day 239)

descriptive

Secondary/protocol endpoint

Area under the concentration versus time curve extrapolated to infinity (AUCinf)

Time frame:Part A (Baseline to Day 85)

concentration, descriptive

Secondary/protocol endpoint

Area under the concentration versus time curve during the dosing interval (AUCtau)

Time frame:Part B (Baseline to Day 113), Part C (Baseline to Day 162), Part D (Baseline to Day 239)

concentration, descriptive

Secondary/protocol endpoint

Maximum observed concentration (Cmax)

Time frame:Part A (Baseline to Day 85), Part B (Baseline to Day 113), Part C (Baseline to Day 162), Part D (Baseline to Day 239)

concentration, descriptive

Secondary/protocol endpoint

Time to maximum observed concentration (Tmax)

Time frame:Part A (Baseline to Day 85), Part B (Baseline to Day 113), Part C (Baseline to Day 162), Part D (Baseline to Day 239)

time to event, event

Secondary/protocol endpoint

Elimination half-life (t1/2)

Time frame:Part A (Baseline to Day 85), Part B (Baseline to Day 113), Part C (Baseline to Day 162), Part D (Baseline to Day 239)

concentration, descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.